Trump administration targets drug and gas affordability

President Donald Trump has announced a new round of voluntary Most Favored Nation (MFN) drug-pricing agreements aimed at improving healthcare affordability. Under this framework, participating manufacturers, including companies such as Bayer, Takeda, and CSL, agree to align U.S. prices with the lowest prices found in other high-income nations like Canada and Japan. The administration credits previous MFN deals with contributing to a 3.1% year-over-year drop in prescription drug prices.

In addition to healthcare, gas prices have begun to decline, with the national average for regular gasoline dipping to approximately $4.01–$4.08 per gallon.

However, concerns remain regarding economic policy, specifically a pending Department of Labor (DOL) proposal regarding Pharmacy Benefit Manager (PBM) fee disclosures. Critics argue the rule is redundant following recent congressional PBM reforms and could increase costs for small businesses, unions, and patients by imposing heavy compliance burdens that favor larger market players over smaller competitors.